Vnitr Lek 2013, 59(8):738-742

Metformin: the overlap of diabetology and oncology

M. Anděl*, P. Škrha, J. Trnka
Centrum výzkumu diabetu, metabolizmu a výživy Ústavu výživy a II. interní kliniky 3. lékařské fakulty UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Michal Anděl, CSc.

Type 2 diabetes moderately increases predisposition for manifestation of tumor disease. Both drugs stimulating insulin secretion (insulin secretagogues) and insulin injection therapy also moderately increases risk of tumor manifestation (OR approx 1.3). According to some reports pyoglitazon therapy could be of increased risk of bladder cancer. On the other hand, hunderds of study on isolated cells, experimental animal models and retrospective studies in patients have shown preventive effect of metformin therapy on manifestation tumors of pancreas, breast, colorectum, liver, endometrium and ovary. More over, the prognosis of diabetic cancer patients on metformin therapy seems be better, than in diabetics without metformin treatment. These data are promising for future use of metformin for prevention and therapy of some malignant tumors.

Keywords: type 2 diabetes mellitus; cancer; antidiabetic therapy; metformin

Received: July 14, 2013; Published: August 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Anděl M, Škrha P, Trnka J. Metformin: the overlap of diabetology and oncology. Vnitr Lek. 2013;59(8):738-742.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Algire C, Zakhikani M, Blouin MJ et al. Metformin attenuates the stimulator effect of a high energy diet in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008; 15: 833-839. Go to original source... Go to PubMed...
    2. Algire C, Moiseeva O, Deschénes-Simard X et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res 2012; 5: 536-543. Go to original source... Go to PubMed...
    3. Anisimov VN, Egormin PA, Bershtein LM et al. Metformin decelarets aging and development of Maďary tumors in HER/2 neu transgenic mice. Bull Exp Biol Med 2005; 139: 721-723. Go to original source... Go to PubMed...
    4. Arai M, Uchiba M, Komura H et al. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J Pharmacol Exp Ther 2010; 334: 206-213. Go to original source... Go to PubMed...
    5. Azoulay L, Yin H, Filton KB et al. The use of pioglitazone and the risk of bladder cancer in poeple with type 2 diabetes: nested case control study. BMJ 2012; 344: e3645. Go to original source... Go to PubMed...
    6. Ben Sahra I, Laurent K, Loubat A et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586. Go to original source... Go to PubMed...
    7. Bodmer M, Becker C, Meier C et al. Use of metformin and the risk of ovarian cancer: a case control analysis. Gynecol Oncol 2001; 123: 200-204. Go to original source... Go to PubMed...
    8. Bodmer M, Becker C, Meier C et al. Use of metofrmin is not associated with a decreased risk of colorectal cancer. A case-control analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 280-286. Go to original source... Go to PubMed...
    9. Butler AE, Campbell-Thompson M, Gurlo T et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humus with increase exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-2604. Go to original source... Go to PubMed...
    10. Carling D, Thornton C, Woods A et al. AMP-activated protein kinase: new regulation, new roles? Biochem J 2012; 445: 11-27. Go to original source... Go to PubMed...
    11. Clarke PR, Hardie DG. Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J 1990; 9: 2439-2441. Go to original source... Go to PubMed...
    12. Coughlin SS, Calte EE, Teras LR et al. Diabetes mellitus as a predator of cancer mortality in a large kohort of US adults. Am J Epidemiol 2004; 159: 1160-1167. Go to original source... Go to PubMed...
    13. Col NF, Ochs L, Springmann V et al. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012; 135: 639-646. Go to original source... Go to PubMed...
    14. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777. Go to original source... Go to PubMed...
    15. Colhoun HM. SDRN Epiemiology Group. Use of insulin glargine and cancer incidence in Scottland. Diabetologia 2009; 52: 1755-1765. Go to original source... Go to PubMed...
    16. El-Mir MY, Nogueira V, Fontaine E et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275: 223-228. Go to original source... Go to PubMed...
    17. Foretz M, Hebrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-2369. Go to original source... Go to PubMed...
    18. Gotlieb WH, Saumet J, Beauchamp MC et al. In vitro metformin anti-neoplastic activity in epithelian ovarian cancer. Gynecol Oncol 2008; 110: 246-250. Go to original source... Go to PubMed...
    19. Gwinn DM, Shackelford DB, Egan DF et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-226. Go to original source... Go to PubMed...
    20. Hemminki A, Markie D, Tomlinson I et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-187. Go to original source... Go to PubMed...
    21. Hemkens LG, Growen U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744. Go to original source... Go to PubMed...
    22. Imamura K, Ogura T, Kishimoto A et al. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001; 287: 562-567. Go to original source... Go to PubMed...
    23. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590. Go to original source... Go to PubMed...
    24. Isakovic A, Harhaji L, Stevanovic D et al. Dual natiglioma action of metformin: cycle cell arest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64: 1290-1302. Go to original source... Go to PubMed...
    25. Jager S, Handschin C, St-Pierre J et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1{alpha}. Proc Natl Acad Sci USA 2007; 104: 12017-12022. Go to original source... Go to PubMed...
    26. Jonasson JM, Ljung M, Talbäck M et al. Insulin glargine use and short term incidence of malignancies - a population based follow-up study in Sweden. Diabetologia 2009; 52: 1742-1754. Go to original source... Go to PubMed...
    27. Jorgensen SB, Nielsen JN, Birk JB et al. The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes 2004; 53: 3074-3081. Go to original source... Go to PubMed...
    28. Kawaguchi T, Osatomi K, Yamashita H et al. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2002; 277: 3829-3835. Go to original source... Go to PubMed...
    29. Koo SH, Flechner L, Qi L et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005; 437: 1109-1114. Go to original source... Go to PubMed...
    30. Leclerc I, Lenzner C, Gourdon L et al. Hepatocyte nuclear factor-4a involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 2001; 50: 1515-1521. Go to original source... Go to PubMed...
    31. Lehman DM, Lorenzo C, Hernandez J et al. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012; 35: 1002-1007. Go to original source... Go to PubMed...
    32. Liao H, Zhou Q, Gu Y et al. Luteinizin hormone facilitates angiogenesis in ovarian epithleian tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep 2012; 27: 1873-1878. Go to PubMed...
    33. Liang J, Shao SH, Hennessy B et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224. Go to original source... Go to PubMed...
    34. Marsin AS, Bertrand L, Rider MH et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000; 10: 1247-1255. Go to original source... Go to PubMed...
    35. Marsin AS, Bouzin C, Bertrand L et al. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J Biol Chem 2002; 277: 30778-30783. Go to original source... Go to PubMed...
    36. Munday MR, Campbell DG, Carling D et al. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur J Biochem 1988; 175: 331-338. Go to original source... Go to PubMed...
    37. Nies AT, Hofmann U, Resch C et al. Proton pump inhibitors inhibit metformin uptake by organic cation transporters. PLoS One 2011; e22163. Go to original source... Go to PubMed...
    38. Pehmoller C, Treebak JT, Birk JB et al. Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle. Am J Physiol Endocrinol Metab 2009; 297: E665-E675. Go to original source... Go to PubMed...
    39. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of beginning. Cancer Discov 2012; 2: 778-790. Go to original source... Go to PubMed...
    40. Romero IL, McCormick A, McEwen KA et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival and chemosensitivity. Obstet Gynecol 2012; 119: 61-67. Go to original source... Go to PubMed...
    41. Rušavý Z, Lacigová S, Kvapil M. Co nám přinesla největší studie v historii diabetologie? Vnitř Lék 2013; 59: 160-164. Go to PubMed...
    42. Shank JJ, Yang K, Ghannan J et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012; 127: 390-397. Go to original source... Go to PubMed...
    43. Smith U, Gale EA. Does insulin therapy influence risk of cancer? Diabetologia 2009; 52: 1699-1708. Go to original source... Go to PubMed...
    44. Schneider MB, Matsuzaki H, Haorah J et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001; 120: 1263-1270. Go to original source... Go to PubMed...
    45. Tang X, Yang L, He Z et al. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One 2012; 7: e51814. Go to original source... Go to PubMed...
    46. Tomimoto A, Endo H, Sugiyama M et al. Metformin suppress intestinal polyp growth in AcpMin/+ mice. Cancer Sci 2008; 99: 2136-2141. Go to original source... Go to PubMed...
    47. Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in population - based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365. Go to original source... Go to PubMed...
    48. Wienecke R, König A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 1995; 270: 16409-16414. Go to original source... Go to PubMed...
    49. Winder WW, Wilson HA, Hardie DG et al. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and cAMP-dependent protein kinase. J Appl Physiol 1997; 82: 219-225. Go to original source... Go to PubMed...
    50. Zakikani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273. Go to original source... Go to PubMed...
    51. Zheng D, MacLean PS, Pohnert SC et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001; 91: 1073-1083. Go to original source... Go to PubMed...
    52. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.